Cellectar Biosciences (DE:NV40)
FRANKFURT:NV40
NV40 Stock Chart & Stats
€0.29
--
Market closed
€0.29
--
Day’s Range― - ―
52-Week Range€0.25 - €10.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€15.53M
Enterprise Value€3.20M
Total Cash (Recent Filing)€8.35M
Total Debt (Recent Filing)€1.53M
Price to Earnings (P/E)―
Beta-0.27
Next Earnings
Aug 19, 2026EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.38
Shares Outstanding7,991,812
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.78
Price to Sales (P/S)0.00
P/FCF Ratio-0.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.93Price Target Upside2978.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.83
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Robust Phase IIb Efficacy For IopofosineThe strong, durable response metrics (high ORR, long median DOR and PFS, responses >36 months in >30% of responders) materially de-risk clinical value of the lead asset, improving probability of regulatory success and future commercial uptake in Waldenström macroglobulinemia.
Clear Regulatory Pathway With Breakthrough DesignationBreakthrough designation and an explicit accelerated-approval/Phase III plan provide structural regulatory advantages: faster interactions, priority review potential, and a defined confirmatory program, which meaningfully shortens development uncertainty versus standard pathways.
Financing Structure Provides Material RunwayThe secured upfront proceeds and contingent milestone funding materially strengthen near-term liquidity and capacity to initiate a Phase III trial and support early commercialization planning, reducing immediate dilution pressure and enabling execution of the development plan.
Bears Say
No Revenue And Persistent Cash BurnAs a pre-revenue developer, the company structurally consumes cash to fund trials and operations; sustained negative operating and free cash flow forces repeated financing, increasing execution risk and making long-term progress dependent on successful clinical/regulatory milestones.
Eroding Equity And Thin Balance Sheet CushionA markedly smaller equity base limits the firm's ability to absorb setbacks or sustain prolonged trial timelines without dilution; lower capital cushion reduces financial flexibility and raises the probability that future funding will dilute existing shareholders.
Milestone- And Market‑contingent Funding RisksA large portion of funding depends on clinical, regulatory and market-performance conditions; if milestones slip or market conditions falter, expected proceeds may not materialize, creating structural execution and liquidity risk that can delay development or force unfavorable financings.
Cellectar Biosciences News
NV40 FAQ
What was Cellectar Biosciences’s price range in the past 12 months?
Cellectar Biosciences lowest stock price was €0.25 and its highest was €10.50 in the past 12 months.
What is Cellectar Biosciences’s market cap?
Cellectar Biosciences’s market cap is €15.53M.
When is Cellectar Biosciences’s upcoming earnings report date?
Cellectar Biosciences’s upcoming earnings report date is Aug 19, 2026 which is in 66 days.
How were Cellectar Biosciences’s earnings last quarter?
Cellectar Biosciences released its earnings results on May 14, 2026. The company reported -€1.154 earnings per share for the quarter, beating the consensus estimate of -€1.636 by €0.482.
Is Cellectar Biosciences overvalued?
According to Wall Street analysts Cellectar Biosciences’s price is currently Undervalued.
Does Cellectar Biosciences pay dividends?
Cellectar Biosciences does not currently pay dividends.
What is Cellectar Biosciences’s EPS estimate?
Cellectar Biosciences’s EPS estimate is -0.42.
How many shares outstanding does Cellectar Biosciences have?
Cellectar Biosciences has 7,991,812 shares outstanding.
What happened to Cellectar Biosciences’s price movement after its last earnings report?
Cellectar Biosciences reported an EPS of -€1.154 in its last earnings report, beating expectations of -€1.636. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cellectar Biosciences?
Currently, no hedge funds are holding shares in DE:NV40
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectar Biosciences
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
NV40 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized major clinical progress for iopofosine (robust Phase IIb 12‑month data with high ORR, durable responses, and regulatory strategy toward accelerated approval) and an oversubscribed financing structure intended to fund late‑stage development. Operational progress on CLR125 and cost discipline were also highlighted. Key risks include a low pre‑financing cash balance, reliance on milestone‑contingent funding with market‑performance conditions, continued net losses, and tight timelines for Phase III initiation and regulatory milestones. On balance, the positive clinical data and financing momentum significantly outweigh the contingent funding and timing risks.View all DE:NV40 earnings summariesNV40 Stock 12 Month Forecast
Average Price Target
€8.93
▲(2978.28% Upside)
Technical Analysis
Options Prices
Currently, No data available
---